90 related articles for article (PubMed ID: 8904466)
1. Taxotere.
Renick-Ettinger A
J Pediatr Oncol Nurs; 1996 Jan; 13(1):43-5. PubMed ID: 8904466
[No Abstract] [Full Text] [Related]
2. Docetaxel (Taxotere): a highly active taxoid with manageable toxicity.
Aapro MS
Semin Oncol; 1995 Apr; 22(2 Suppl 4):1-2. PubMed ID: 7740325
[No Abstract] [Full Text] [Related]
3. Docetaxel (Taxotere) in the treatment of cancer.
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):1-2. PubMed ID: 10810931
[No Abstract] [Full Text] [Related]
4. Docetaxel (Taxotere): preclinical and general clinical information.
Earhart RH
Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
[TBL] [Abstract][Full Text] [Related]
5. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
6. Taxoids, a new class of antitumour agents of plant origin: recent results.
Potier P; Guéritte-Voegelein F; Guénard D
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S21-3. PubMed ID: 7909940
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel.
Aikin JL
Clin J Oncol Nurs; 1999 Apr; 3(2):83-4. PubMed ID: 10633618
[No Abstract] [Full Text] [Related]
8. Conclusion: the place of docetaxel (Taxotere) in future therapy.
Khayat D
Anticancer Drugs; 1996 Aug; 7 Suppl 2():53. PubMed ID: 8862713
[No Abstract] [Full Text] [Related]
9. Taxotere becomes first drug to outperform Adriamycin.
Ir Med J; 1997; 90(4):156. PubMed ID: 9267101
[No Abstract] [Full Text] [Related]
10. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
11. Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere).
Cheson BD; Arbuck SG; Phillips PH
Oncology (Williston Park); 1993 Sep; 7(9):51-2. PubMed ID: 8105859
[No Abstract] [Full Text] [Related]
12. Taxol and taxotere in bladder cancer: in vitro activity and urine stability.
Rangel C; Niell H; Miller A; Cox C
Cancer Chemother Pharmacol; 1994; 33(6):460-4. PubMed ID: 7907952
[TBL] [Abstract][Full Text] [Related]
13. Taxotere shows significant antitumor activity in anthracycline-resistant breast cancer patients.
Oncology (Williston Park); 1994 Sep; 8(9):112. PubMed ID: 7993720
[No Abstract] [Full Text] [Related]
14. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Kris MG; Millward M
Semin Oncol; 1999 Jun; 26(3 Suppl 10):1-2. PubMed ID: 10437742
[No Abstract] [Full Text] [Related]
15. [Taxotere: the first drug better than acrdiamycin, the most frequently used drug in the treatment of metastasized breast cancer. Phase III study shows a better response than standard treatment].
Oncologica; 1997 Aug; 14(3):23-4. PubMed ID: 9481342
[No Abstract] [Full Text] [Related]
16. The clinical rationale for developing docetaxel (Taxotere).
Armand JP
Anticancer Drugs; 1996 Aug; 7 Suppl 2():37-9. PubMed ID: 8862710
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: recent results and future developments.
Rosell R
Semin Oncol; 1999 Jun; 26(3 Suppl 11):1-3. PubMed ID: 10458202
[No Abstract] [Full Text] [Related]
18. The development of docetaxel (Taxotere) in non-small cell lung cancer.
Kris MG; Miller VA; Ng KK; Grant SC
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
[No Abstract] [Full Text] [Related]
19. Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Vogelzang NJ
Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-2. PubMed ID: 10604260
[No Abstract] [Full Text] [Related]
20. Taxotere inhibits in-vitro growth of human colonic cancer cell lines.
Karantanis E; Nicholson S; Morris DL
Eur J Surg Oncol; 1994 Dec; 20(6):653-7. PubMed ID: 7995417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
